BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38133601)

  • 1. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
    Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
    Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
    Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
    Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study).
    Rolland B; Lions C; Di Beo V; Carrieri P; Authier N; Barré T; Delorme J; Mathurin P; Bailly F; Protopopescu C; Marcellin F
    Harm Reduct J; 2022 Oct; 19(1):119. PubMed ID: 36303159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
    Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France.
    Djaogol T; Fontaine H; Baudoin M; Protopopescu C; Marcellin F; Dorival C; Simony M; Petrov-Sanchez V; Bourlière M; Delarocque-Astagneau E; Pol S; Carrat F; Carrieri P;
    Liver Int; 2021 Oct; 41(10):2328-2340. PubMed ID: 33590608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
    HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
    Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
    Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
    J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
    Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
    BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
    Pageaux GP; Nzinga CL; Ganne N; Samuel D; Dorival C; Zoulim F; Cagnot C; Decaens T; Thabut D; Asselah T; Mathurin P; Habersetzer F; Bronowicki JP; Guyader D; Rosa I; Leroy V; Chazouilleres O; de Ledinghen V; Bourliere M; Causse X; Cales P; Metivier S; Loustaud-Ratti V; Riachi G; Alric L; Gelu-Simeon M; Minello A; Gournay J; Geist C; Tran A; Abergel A; Portal I; d'Alteroche L; Raffi F; Fontaine H; Carrat F; Pol S;
    BMC Infect Dis; 2022 Jan; 22(1):94. PubMed ID: 35086481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.
    Chen PH; Yenokyan K; Fojo AT; Hutton HE; Lesko CR; McCaul ME; Yang C; Cachay ER; Crane HM; Jacobson JM; Kim HN; Kitahata MM; Mayer KH; Moore RD; Napravnik S; Saag M; Lau B; Chander G
    Drug Alcohol Depend; 2022 Dec; 241():109673. PubMed ID: 36332596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection.
    Yin X; Kong L; Du P; Jung J
    AIDS Care; 2022 Oct; 34(10):1330-1337. PubMed ID: 34581640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
    de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
    J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.